-
264%
OncQuer TM Scout LB EGFR Resi ...
Identification gene mutations leading to resistance to EGFR therapyOncQuer TM Scout LB EGFR Resi ...
Identification gene mutations leading to resistance to EGFR therapy -
264%
OncQuer TM Scout LB EGFR Resp ...
Identification gene mutations leading to sensitivity and resistance to EGFR therapyOncQuer TM Scout LB EGFR Resp ...
Identification gene mutations leading to sensitivity and resistance to EGFR therapy -
264%
OncQuer TM Scout LB EGFR Sens ...
Identification gene mutations leading to sensitivity to EGFR therapyOncQuer TM Scout LB EGFR Sens ...
Identification gene mutations leading to sensitivity to EGFR therapy -
264%
OncQuer TM Scout LB KRAS Muta ...
Identification gene mutations leading to resistance to EGFR therapyOncQuer TM Scout LB KRAS Muta ...
Identification gene mutations leading to resistance to EGFR therapy -
264%
OncQuer TM 500 gene panel (Ad ...
Identification of therapeutically relevant gene mutations for CancerOncQuer TM 500 gene panel (Ad ...
Identification of therapeutically relevant gene mutations for Cancer -
264%
OncQuer TM 500 gene panel (Ba ...
Identification of therapeutically relevant gene mutations for CancerOncQuer TM 500 gene panel (Ba ...
Identification of therapeutically relevant gene mutations for Cancer -
272%
OncQuer TM Endometrial Cancer ...
Identification of therapeutically relevant gene mutations for CancerOncQuer TM Endometrial Cancer ...
Identification of therapeutically relevant gene mutations for Cancer -
264%
OncQuer TM Germline Mutation P ...
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected…OncQuer TM Germline Mutation P ...
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected… -
264%
OncQuer TM HRD testing
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer TM HRD testing
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
